Targeted Delivery of AGO-2 to Myocardial Mitochondria via Functionalized Nanoparticles Attenuates Oxidative Stress in Diabetic Cardiomyopathy.

Du W, Jiang Y, Wu L, Liang Y, Wu YP, Liu H, Chen TW

ACS applied materials & interfaces25 Nov 2025Cited by 3 (Europe PMC)

PMID41288605PMCIDPMC12874382DOI10.1021/acsami.5c15154PepBankPUB-41288605

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Activity measurement
The nanocarrier ESC-AGO-2 (AGO-2 on an iron oxide core with SS‑31 and a cardiac-homing peptide) localized effectively to mitochondria in vitro and in vivo.
In plain wordsIn lab tests and mice, a nanocarrier with SS‑31 delivered AGO-2 to heart mitochondria.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseMitochondrial localization of ESC-AGO-2
Study
mousen: not reported in source
diabetic mice (in vivo) and cells (in vitro)
Outcome group
Mitochondrial function · Cardiovascular
Source sentences
Summary
ESC-AGO-2 effectively localized to mitochondria in vitro and in vivo
1 context sentence(design, population, supporting numbers)
Summary · context
We employed an extremely small iron oxide (ESIO) nanoparticle core functionalized with cardiac-homing peptide (CHP) and the mitochondrial-targeting peptide SS-31 to construct a targeted platform, denoted ESIO-SS-31-CHP (ESC).
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4128860501
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
ESC-AGO-2 improved mitochondrial performance in diabetic cardiomyopathy models.
In plain wordsIn diabetic models, a nanocarrier delivering AGO-2 improved mitochondrial performance.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseMitochondrial performance
Study
mousen: not reported in source
diabetic mice (in vivo) and cells (in vitro)
Outcome group
Mitochondrial function · Cardiovascular
Source sentences
Summary
leading to improved mitochondrial performance, reduced oxidative damage
1 context sentence(design, population, supporting numbers)
Summary · context
We employed an extremely small iron oxide (ESIO) nanoparticle core functionalized with cardiac-homing peptide (CHP) and the mitochondrial-targeting peptide SS-31 to construct a targeted platform, denoted ESIO-SS-31-CHP (ESC).
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4128860502
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
ESC-AGO-2 reduced oxidative damage in diabetic cardiomyopathy models.
In plain wordsIn diabetic models, a nanocarrier delivering AGO-2 reduced oxidative damage.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseOxidative damage
Study
mousen: not reported in source
diabetic mice (in vivo) and cells (in vitro)
Outcome group
Inflammation markers · Cardiovascular
Source sentences
Summary
reduced oxidative damage, and attenuated inflammatory responses.
1 context sentence(design, population, supporting numbers)
Summary · context
We employed an extremely small iron oxide (ESIO) nanoparticle core functionalized with cardiac-homing peptide (CHP) and the mitochondrial-targeting peptide SS-31 to construct a targeted platform, denoted ESIO-SS-31-CHP (ESC).
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4128860503
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
ESC-AGO-2 attenuated inflammatory responses in diabetic cardiomyopathy models.
In plain wordsIn diabetic models, a nanocarrier delivering AGO-2 reduced inflammation.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammatory responses
Study
mousen: not reported in source
diabetic mice (in vivo) and cells (in vitro)
Outcome group
Inflammation markers · Cardiovascular
Source sentences
Summary
attenuated inflammatory responses.
1 context sentence(design, population, supporting numbers)
Summary · context
We employed an extremely small iron oxide (ESIO) nanoparticle core functionalized with cardiac-homing peptide (CHP) and the mitochondrial-targeting peptide SS-31 to construct a targeted platform, denoted ESIO-SS-31-CHP (ESC).
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4128860504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.